Serena Altamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Serena Altamura has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Benedetta Cinque
Department of Life, Health & Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy
14 shared publications - Francesca Lombardi
Department of Life, Health & Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy
14 shared publications - Paola Palumbo
Department of Life, Health & Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy
13 shared publications - Davide Pietropaoli
Department of Life, Health & Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy
12 shared publications - Francesca Rosaria Augello
Department of Life, Health & Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy
11 shared publications - Alessia Ciafarone
Department of Physical and Chemical Sciences, University of L’Aquila, 67100 L’Aquila, Italy
10 shared publications
Latest Publications
- Open Access
- 25 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9528
Lip Squamous Cell Carcinoma: A Conceptual Framework for Integrating Molecular, Immune and Microenvironmental Drivers
Lip squamous cell carcinoma (LSCC) is a distinct subtype of head and neck squamous cell carcinoma strongly associated with ultraviolet (UV) radiation exposure and characterized by unique molecular, immune, and microenvironmental features. Although UV-induced photodamage represents the principal initiating event, increasing evidence indicates that LSCC progression results from complex interactions among genetic and epigenetic alterations, dysregulated signaling pathways, chronic inflammation, immune dysregulation, host–microbiome dynamics, and tumor microenvironment (TME) remodeling. Recent advances have expanded the traditional view of LSCC by highlighting the contributions of UV-induced DNA damage, tumor protein p53 (TP53) alterations, epigenetic reprogramming, aberrant activation of key signaling pathways, and progressive immune escape mechanisms. In parallel, growing attention has focused on the role of cancer-associated fibroblasts (CAFs), stromal remodeling, microbial dysbiosis, and disruption of the microbiome–immune–metabolic axis as important modulators of disease progression and biological heterogeneity. Emerging biomarkers, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), epigenetic signatures, liquid-biopsy analytes, immune-related markers, and microbiome-associated profiles, together with artificial intelligence (AI)-based analytical approaches, are creating new opportunities for diagnosis, risk stratification, disease monitoring, and precision oncology. Rather than providing a conventional descriptive overview, this review proposes an integrated conceptual framework in which molecular, immune, microbial, and microenvironmental drivers interact through continuous bidirectional crosstalk to shape LSCC initiation, progression, therapeutic responsiveness, and clinical heterogeneity. This system-oriented perspective may provide a foundation for future biomarker-guided and biologically informed approaches to LSCC management.
- 25 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9528
Open AccessLip Squamous Cell Carcinoma: A Conceptual Framework for Integrating Molecular, Immune and Microenvironmental Drivers
Lip squamous cell carcinoma (LSCC) is a distinct subtype of head and neck squamous cell carcinoma strongly associated with ultraviolet (UV) radiation exposure and characterized by unique molecular, immune, and microenvironmental features. Although UV-induced photodamage represents the principal initiating event, increasing evidence indicates that LSCC progression results from complex interactions among genetic and epigenetic alterations, dysregulated signaling pathways, chronic inflammation, immune dysregulation, host–microbiome dynamics, and tumor microenvironment (TME) remodeling. Recent advances have expanded the traditional view of LSCC by highlighting the contributions of UV-induced DNA damage, tumor protein p53 (TP53) alterations, epigenetic reprogramming, aberrant activation of key signaling pathways, and progressive immune escape mechanisms. In parallel, growing attention has focused on the role of cancer-associated fibroblasts (CAFs), stromal remodeling, microbial dysbiosis, and disruption of the microbiome–immune–metabolic axis as important modulators of disease progression and biological heterogeneity. Emerging biomarkers, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), epigenetic signatures, liquid-biopsy analytes, immune-related markers, and microbiome-associated profiles, together with artificial intelligence (AI)-based analytical approaches, are creating new opportunities for diagnosis, risk stratification, disease monitoring, and precision oncology. Rather than providing a conventional descriptive overview, this review proposes an integrated conceptual framework in which molecular, immune, microbial, and microenvironmental drivers interact through continuous bidirectional crosstalk to shape LSCC initiation, progression, therapeutic responsiveness, and clinical heterogeneity. This system-oriented perspective may provide a foundation for future biomarker-guided and biologically informed approaches to LSCC management.
- Open Access
- 11 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (20) , 9012
Oral Nitrate-Reducing Bacteria and Nitric Oxide Homeostasis: Functional Host–Microbe Interactions in Oral and Vascular Health
Nitric oxide (NO) is a key regulator of vascular homeostasis and host–microbe interactions. In addition to the endogenous nitric oxide synthase (NOS) pathway, the enterosalivary nitrate–nitrite–NO pathway provides an alternative source of NO and critically depends on oral nitrate-reducing bacteria (ONRB). This review examines the oral microbiome–NO axis and its role in nitrate metabolism, NO homeostasis, and oral–systemic interactions. A narrative review integrating microbiological, mechanistic, and clinical evidence on oral nitrate metabolism, ONRB activity, and their impact on oral and systemic outcomes, including dietary and antiseptic interventions. The functional activity and nitrate-reducing capacity of the oral microbiome are key determinants of nitrate reduction and systemic NO bioavailability. Oral dysbiosis, periodontal disease, and antiseptic mouthwash use impair ONRB activity and nitrite production, potentially affecting vascular function and blood pressure. Conversely, dietary nitrate enhances ONRB activity and nitrate-to-nitrite conversion, supporting oral and vascular health. Interindividual variability, partly influenced by sex-related factors, may contribute to heterogeneous responses. The oral microbiome–NO axis represents a functional interface between host physiology and microbial metabolism, linking oral ecology with vascular regulation. Through their activity, ONRB contribute to NO homeostasis, highlighting nitrate bioactivation as an important component of host–microbe interactions with implications for oral and systemic physiology. Recognition of this pathway expands current understanding of host–microbe cooperation in NO homeostasis and may inform future microbiome-based approaches to support oral and cardiovascular health.
- 11 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (20) , 9012
Open AccessOral Nitrate-Reducing Bacteria and Nitric Oxide Homeostasis: Functional Host–Microbe Interactions in Oral and Vascular Health
Nitric oxide (NO) is a key regulator of vascular homeostasis and host–microbe interactions. In addition to the endogenous nitric oxide synthase (NOS) pathway, the enterosalivary nitrate–nitrite–NO pathway provides an alternative source of NO and critically depends on oral nitrate-reducing bacteria (ONRB). This review examines the oral microbiome–NO axis and its role in nitrate metabolism, NO homeostasis, and oral–systemic interactions. A narrative review integrating microbiological, mechanistic, and clinical evidence on oral nitrate metabolism, ONRB activity, and their impact on oral and systemic outcomes, including dietary and antiseptic interventions. The functional activity and nitrate-reducing capacity of the oral microbiome are key determinants of nitrate reduction and systemic NO bioavailability. Oral dysbiosis, periodontal disease, and antiseptic mouthwash use impair ONRB activity and nitrite production, potentially affecting vascular function and blood pressure. Conversely, dietary nitrate enhances ONRB activity and nitrate-to-nitrite conversion, supporting oral and vascular health. Interindividual variability, partly influenced by sex-related factors, may contribute to heterogeneous responses. The oral microbiome–NO axis represents a functional interface between host physiology and microbial metabolism, linking oral ecology with vascular regulation. Through their activity, ONRB contribute to NO homeostasis, highlighting nitrate bioactivation as an important component of host–microbe interactions with implications for oral and systemic physiology. Recognition of this pathway expands current understanding of host–microbe cooperation in NO homeostasis and may inform future microbiome-based approaches to support oral and cardiovascular health.
- Open Access
- 14 August 2026
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 6 (3) , 32
Breast Implant-Associated Conditions: Exploring the Potential Role of Chronic Inflammation and the Host–Implant–Microbiome Interface
Background/Objectives: Breast implants are widely used in aesthetic and reconstructive surgery. Although they are not associated with an increased risk of breast carcinoma, growing attention has focused on implant-associated conditions, including breast implant-associated malignancies, breast implant illness (BII), and autoimmune or inflammatory manifestations. This review examines current evidence and explores the potential role of chronic inflammation and the host–implant–microbiome interface in these conditions. Methods: A narrative review was conducted focusing on implant-associated malignancies, BII, autoimmune manifestations, chronic inflammation, implant-associated biofilms, and host–implant interactions. Evidence from oncology, immunology, microbiology, and biomaterials research was integrated to evaluate potential mechanisms underlying implant-associated local and systemic manifestations. Results: Recent evidence suggests that prolonged host–implant interactions, persistent foreign body responses, implant-associated biofilms, microbial persistence, and chronic immune stimulation may contribute to long-term alterations within the peri-implant environment. These mechanisms have been proposed as potential contributors to breast implant-associated malignancies, as well as to systemic manifestations such as BII and autoimmune or inflammatory conditions. Although BII and autoimmune/inflammatory syndrome induced by adjuvants (ASIA) have received increasing attention, causal relationships with breast implants remain unproven, and available evidence is limited by methodological heterogeneity, lack of standardized diagnostic criteria, and potential confounding factors. Conclusions: Emerging evidence highlights a complex interplay among implanted biomaterials, microbial biofilms, and host immune responses. The host–implant–microbiome interface may promote a biological environment that promotes persistent immune stimulation and chronic low-grade inflammation, providing a biologically plausible framework for interpreting heterogeneous implant-associated conditions. Further studies are needed to clarify the role of host–implant–microbiome interactions in implant-associated local and systemic manifestations.
- 14 August 2026
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 6 (3) , 32
Open AccessBreast Implant-Associated Conditions: Exploring the Potential Role of Chronic Inflammation and the Host–Implant–Microbiome Interface
Background/Objectives: Breast implants are widely used in aesthetic and reconstructive surgery. Although they are not associated with an increased risk of breast carcinoma, growing attention has focused on implant-associated conditions, including breast implant-associated malignancies, breast implant illness (BII), and autoimmune or inflammatory manifestations. This review examines current evidence and explores the potential role of chronic inflammation and the host–implant–microbiome interface in these conditions. Methods: A narrative review was conducted focusing on implant-associated malignancies, BII, autoimmune manifestations, chronic inflammation, implant-associated biofilms, and host–implant interactions. Evidence from oncology, immunology, microbiology, and biomaterials research was integrated to evaluate potential mechanisms underlying implant-associated local and systemic manifestations. Results: Recent evidence suggests that prolonged host–implant interactions, persistent foreign body responses, implant-associated biofilms, microbial persistence, and chronic immune stimulation may contribute to long-term alterations within the peri-implant environment. These mechanisms have been proposed as potential contributors to breast implant-associated malignancies, as well as to systemic manifestations such as BII and autoimmune or inflammatory conditions. Although BII and autoimmune/inflammatory syndrome induced by adjuvants (ASIA) have received increasing attention, causal relationships with breast implants remain unproven, and available evidence is limited by methodological heterogeneity, lack of standardized diagnostic criteria, and potential confounding factors. Conclusions: Emerging evidence highlights a complex interplay among implanted biomaterials, microbial biofilms, and host immune responses. The host–implant–microbiome interface may promote a biological environment that promotes persistent immune stimulation and chronic low-grade inflammation, providing a biologically plausible framework for interpreting heterogeneous implant-associated conditions. Further studies are needed to clarify the role of host–implant–microbiome interactions in implant-associated local and systemic manifestations.
- Open Access
- 13 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5356
Oral Barrier Immunometabolism in Chronic Low-Grade Inflammation: Molecular Mechanisms and Systemic Implications
Chronic low-grade inflammation is a hallmark of aging and a major driver of metabolic and degenerative diseases. While systemic immune dysfunction has been widely investigated, the contribution of barrier tissues to persistent inflammatory signaling remains incompletely defined. The oral mucosa represents a uniquely exposed barrier, continuously challenged by microbial, mechanical, and metabolic stressors and characterized by a specialized immune architecture. Here, we synthesize current evidence supporting the oral barrier as an active immunometabolic interface linking local immune activation to systemic inflammatory tone. Spatially organized epithelial, neutrophil, and antigen-presenting cell (APC) compartments coordinate immune responses tightly coupled to metabolic reprogramming, including hypoxia-inducible factor-1α (HIF-1α)-dependent glycolysis and mitochondrial reactive oxygen species (mtROS) production. In parallel, the oral microbiota provides ligands and metabolites such as lipopolysaccharide (LPS), short-chain fatty acids (SCFAs), and succinate, which activate pattern-recognition receptors (PRRs), including toll-like receptors (TLRs) and the NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome, thereby sustaining nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB)-mediated inflammatory signaling. Barrier disruption and dysbiosis promote microbial translocation and persistent innate immune activation, while saliva and gingival crevicular fluid facilitate systemic dissemination of inflammatory mediators. Overall, sustained immunometabolic engagement at the oral barrier emerges as a key driver of chronic low-grade systemic inflammation and a potential therapeutic target in inflammaging.
- 13 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5356
Open AccessOral Barrier Immunometabolism in Chronic Low-Grade Inflammation: Molecular Mechanisms and Systemic Implications
Chronic low-grade inflammation is a hallmark of aging and a major driver of metabolic and degenerative diseases. While systemic immune dysfunction has been widely investigated, the contribution of barrier tissues to persistent inflammatory signaling remains incompletely defined. The oral mucosa represents a uniquely exposed barrier, continuously challenged by microbial, mechanical, and metabolic stressors and characterized by a specialized immune architecture. Here, we synthesize current evidence supporting the oral barrier as an active immunometabolic interface linking local immune activation to systemic inflammatory tone. Spatially organized epithelial, neutrophil, and antigen-presenting cell (APC) compartments coordinate immune responses tightly coupled to metabolic reprogramming, including hypoxia-inducible factor-1α (HIF-1α)-dependent glycolysis and mitochondrial reactive oxygen species (mtROS) production. In parallel, the oral microbiota provides ligands and metabolites such as lipopolysaccharide (LPS), short-chain fatty acids (SCFAs), and succinate, which activate pattern-recognition receptors (PRRs), including toll-like receptors (TLRs) and the NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome, thereby sustaining nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB)-mediated inflammatory signaling. Barrier disruption and dysbiosis promote microbial translocation and persistent innate immune activation, while saliva and gingival crevicular fluid facilitate systemic dissemination of inflammatory mediators. Overall, sustained immunometabolic engagement at the oral barrier emerges as a key driver of chronic low-grade systemic inflammation and a potential therapeutic target in inflammaging.
- Open Access
- 24 January 2026
- Published by Wiley in Journal of Food Biochemistry
- Vol. 2026 (1)
Inhibitory Effect of Levilactobacillus brevis on Salivary α‐Amylase: Evidence From In Vivo and In Vitro Study
Scope: Human salivary α‐amylase (sAA) is a therapeutic target for various pathological oral conditions. Several studies have reported that different probiotic strains can inhibit α‐amylase in vitro . However, the mechanisms behind remain largely unknown. To explore this topic, we focused on Levilactobacillus brevis (L. brevis) , a probiotic species known for its beneficial effects on oral health. Methods and Results: The effect of L. brevis on sAA activity was evaluated in vivo by analyzing saliva samples from healthy subjects involved in a randomized, double‐blind, placebo‐controlled study. Additionally, we assessed the effects of probiotic lysate in vitro using a commercial sAA. An amylase‐binding assay was conducted to investigate the interaction between probiotic soluble components and the enzyme. Our findings demonstrate that L. brevis effectively inhibits α‐amylase activity, supporting its positive role in promoting both oral and systemic health. We also observed a similar effect on pancreatic α‐amylase. Conclusion: Our data provide the first evidence of a direct interaction between α‐amylase and bioactive molecules from L. brevis , suggesting that the observed effects could be due to the ability of these probiotic‐derived molecules to bind and inhibit α‐amylase activity. This research expands our understanding of the anticariogenic and antihyperglycemic properties of specific probiotics. Trial Registration: ClinicalTrials.gov identifier: NCT06457724
- 24 January 2026
- Published by Wiley in Journal of Food Biochemistry
- Vol. 2026 (1)
Open AccessInhibitory Effect of Levilactobacillus brevis on Salivary α‐Amylase: Evidence From In Vivo and In Vitro Study
Scope: Human salivary α‐amylase (sAA) is a therapeutic target for various pathological oral conditions. Several studies have reported that different probiotic strains can inhibit α‐amylase in vitro . However, the mechanisms behind remain largely unknown. To explore this topic, we focused on Levilactobacillus brevis (L. brevis) , a probiotic species known for its beneficial effects on oral health. Methods and Results: The effect of L. brevis on sAA activity was evaluated in vivo by analyzing saliva samples from healthy subjects involved in a randomized, double‐blind, placebo‐controlled study. Additionally, we assessed the effects of probiotic lysate in vitro using a commercial sAA. An amylase‐binding assay was conducted to investigate the interaction between probiotic soluble components and the enzyme. Our findings demonstrate that L. brevis effectively inhibits α‐amylase activity, supporting its positive role in promoting both oral and systemic health. We also observed a similar effect on pancreatic α‐amylase. Conclusion: Our data provide the first evidence of a direct interaction between α‐amylase and bioactive molecules from L. brevis , suggesting that the observed effects could be due to the ability of these probiotic‐derived molecules to bind and inhibit α‐amylase activity. This research expands our understanding of the anticariogenic and antihyperglycemic properties of specific probiotics. Trial Registration: ClinicalTrials.gov identifier: NCT06457724
- Open Access
- 30 December 2025
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 5, 1003233
The anti-inflammatory and analgesic potential of the probiotic Streptococcus thermophilus via inhibition of endocannabinoid-degrading enzymes: a preliminary in vitro study
Aim: The benefit of topical application of probiotics on pain and itching associated with skin disorders has become an increasingly intriguing topic in recent years. These effects are mainly associated with the anti-inflammatory activity of probiotics. Given the crucial role of the endocannabinoid system (ECS) in skin pathophysiology, here, the ability of Streptococcus thermophilus was evaluated, in comparison with Lactobacillus acidophilus, to inhibit two enzymes involved in endocannabinoid (eCB) degradation: fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). Methods: Bacterial lysates were obtained from both probiotics. FAAH and MAGL activities were assayed using fluorometric and colorimetric methods. The effect of probiotic lysates on FAAH and MAGL activities was also evaluated on human keratinocytes stimulated with lipopolysaccharide (LPS). Results: S. thermophilus inhibited both FAAH and MAGL, although to varying extents. In comparison, L. acidophilus had a minimal effect on FAAH and did not influence MAGL activity. Conclusions: Although preliminary, our findings suggest that S. thermophilus may exert both potential analgesic and anti-inflammatory effects by modulating the ECS and reducing the degradation of EC, known to play a key role in immune regulation and inflammation. Results presented confirm the selective actions of probiotics and propose a novel mechanism that may contribute to the beneficial effects of S. thermophilus in alleviating signs and symptoms associated with inflammatory skin conditions. Our evidence shows significant inhibitory activity of S. thermophilus on FAAH and MAGL activity, suggesting its ability to influence skin conditions by modulating ECS and preventing the eCB degradation.
- 30 December 2025
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 5, 1003233
Open AccessThe anti-inflammatory and analgesic potential of the probiotic Streptococcus thermophilus via inhibition of endocannabinoid-degrading enzymes: a preliminary in vitro study
Aim: The benefit of topical application of probiotics on pain and itching associated with skin disorders has become an increasingly intriguing topic in recent years. These effects are mainly associated with the anti-inflammatory activity of probiotics. Given the crucial role of the endocannabinoid system (ECS) in skin pathophysiology, here, the ability of Streptococcus thermophilus was evaluated, in comparison with Lactobacillus acidophilus, to inhibit two enzymes involved in endocannabinoid (eCB) degradation: fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). Methods: Bacterial lysates were obtained from both probiotics. FAAH and MAGL activities were assayed using fluorometric and colorimetric methods. The effect of probiotic lysates on FAAH and MAGL activities was also evaluated on human keratinocytes stimulated with lipopolysaccharide (LPS). Results: S. thermophilus inhibited both FAAH and MAGL, although to varying extents. In comparison, L. acidophilus had a minimal effect on FAAH and did not influence MAGL activity. Conclusions: Although preliminary, our findings suggest that S. thermophilus may exert both potential analgesic and anti-inflammatory effects by modulating the ECS and reducing the degradation of EC, known to play a key role in immune regulation and inflammation. Results presented confirm the selective actions of probiotics and propose a novel mechanism that may contribute to the beneficial effects of S. thermophilus in alleviating signs and symptoms associated with inflammatory skin conditions. Our evidence shows significant inhibitory activity of S. thermophilus on FAAH and MAGL activity, suggesting its ability to influence skin conditions by modulating ECS and preventing the eCB degradation.
- Open Access
- 26 October 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (11) , 1282
Exploring the Anticancer Potential of the Multistrain Probiotic Formulation OxxySlab in Bladder Cancer Cell Lines
Bladder cancer (BC), particularly its muscle-invasive subtype (MIBC), remains a clinical challenge due to high recurrence and limited therapeutic options. Emerging evidence suggests that probiotics may offer selective anticancer effects while preserving healthy tissue. In this study, we evaluated the antitumor potential of OxxySlab, a multistrain probiotic formulation, in two BC cell lines (T24 and 5637) and a non-tumorigenic urothelial cell line (SV-HUC1). OxxySlab lysate dose-dependently inhibited BC cell proliferation, clonogenicity, and migration, while sparing normal cells. Mechanistically, the treatment suppressed epithelial–mesenchymal transition (EMT), induced senescence, and disrupted redox homeostasis in malignant cells. These effects were associated with the induction of oxidative stress and impaired antioxidant defenses. Co-treatment with vitamin C attenuated ROS accumulation and senescence, implicating oxidative stress as a key mediator. Notably, SV-HUC1 cells retained viability and phenotype, confirming the formulation’s selectivity. Overall, these findings support OxxySlab as a promising adjunctive strategy in BC therapy, capable of reducing tumor aggressiveness through redox-mediated senescence and EMT inhibition without harming normal urothelial cells.
- 26 October 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (11) , 1282
Open AccessExploring the Anticancer Potential of the Multistrain Probiotic Formulation OxxySlab in Bladder Cancer Cell Lines
Bladder cancer (BC), particularly its muscle-invasive subtype (MIBC), remains a clinical challenge due to high recurrence and limited therapeutic options. Emerging evidence suggests that probiotics may offer selective anticancer effects while preserving healthy tissue. In this study, we evaluated the antitumor potential of OxxySlab, a multistrain probiotic formulation, in two BC cell lines (T24 and 5637) and a non-tumorigenic urothelial cell line (SV-HUC1). OxxySlab lysate dose-dependently inhibited BC cell proliferation, clonogenicity, and migration, while sparing normal cells. Mechanistically, the treatment suppressed epithelial–mesenchymal transition (EMT), induced senescence, and disrupted redox homeostasis in malignant cells. These effects were associated with the induction of oxidative stress and impaired antioxidant defenses. Co-treatment with vitamin C attenuated ROS accumulation and senescence, implicating oxidative stress as a key mediator. Notably, SV-HUC1 cells retained viability and phenotype, confirming the formulation’s selectivity. Overall, these findings support OxxySlab as a promising adjunctive strategy in BC therapy, capable of reducing tumor aggressiveness through redox-mediated senescence and EMT inhibition without harming normal urothelial cells.
- Open Access
Multi-Strain Probiotic Lysate Attenuates TGF-β1-Induced Intestinal Fibrosis and EMT Modulating Smad, Akt, and WNT/β-Catenin Pathways
Intestinal fibrosis is a common complication of inflammatory bowel diseases (IBD), and, to date, effective and safe antifibrotic drugs are still lacking. Emerging evidence suggests that probiotics may provide novel strategies to counteract fibrotic processes. In this study, we evaluated the anti-fibrotic potential of a multi-strain probiotic formulation, OxxySlabTM, using in vitro models of intestinal fibrosis and epithelial-to-mesenchymal transition (EMT). Human intestinal fibroblasts (CCD-18Co cell line) and epithelial cells (Caco-2 cell line, IECs) were stimulated with transforming growth factor-β1 (TGF-β1) to induce fibrotic and EMT phenotypes, respectively. Treatment with OxxySlab modulated cell proliferation and fibrosis-related markers, which we assessed through CCK-8 assay, Western blotting, and immunofluorescence. The probiotic lysate inhibited both canonical and non-canonical TGF-β1 signaling pathways, and it also reduced TGF-β1 gene expression in activated myofibroblasts, as shown by RT-qPCR. Furthermore, probiotic treatment reversed EMT features by restoring epithelial markers and downregulating mesenchymal markers. These findings highlight the beneficial effects of the multi-strain probiotic formulation as an adjunctive therapeutic agent targeting key pathways involved in intestinal fibrosis.
Open AccessMulti-Strain Probiotic Lysate Attenuates TGF-β1-Induced Intestinal Fibrosis and EMT Modulating Smad, Akt, and WNT/β-Catenin Pathways
Intestinal fibrosis is a common complication of inflammatory bowel diseases (IBD), and, to date, effective and safe antifibrotic drugs are still lacking. Emerging evidence suggests that probiotics may provide novel strategies to counteract fibrotic processes. In this study, we evaluated the anti-fibrotic potential of a multi-strain probiotic formulation, OxxySlabTM, using in vitro models of intestinal fibrosis and epithelial-to-mesenchymal transition (EMT). Human intestinal fibroblasts (CCD-18Co cell line) and epithelial cells (Caco-2 cell line, IECs) were stimulated with transforming growth factor-β1 (TGF-β1) to induce fibrotic and EMT phenotypes, respectively. Treatment with OxxySlab modulated cell proliferation and fibrosis-related markers, which we assessed through CCK-8 assay, Western blotting, and immunofluorescence. The probiotic lysate inhibited both canonical and non-canonical TGF-β1 signaling pathways, and it also reduced TGF-β1 gene expression in activated myofibroblasts, as shown by RT-qPCR. Furthermore, probiotic treatment reversed EMT features by restoring epithelial markers and downregulating mesenchymal markers. These findings highlight the beneficial effects of the multi-strain probiotic formulation as an adjunctive therapeutic agent targeting key pathways involved in intestinal fibrosis.
- Open Access
- 6 September 2025
- Published by MDPI AG in Applied Sciences
- Vol. 15 (17) , 9790
Application of AI-Driven Software Diagnocat in Managing Diagnostic Imaging in Dentistry: A Retrospective Study
Background: This study investigates the diagnostic reliability of an artificial intelligence (AI)-based software (Diagnocat) in caries, dental restorations, missing teeth, and periodontal bone loss on panoramic radiographs (PRs), comparing its performance with evaluations from three independent dental experts serving as ground truth. Methods: A total of 104 PRs were analyzed using Diagnocat, which assigned a likelihood score (0–100%) for each condition. The same images were independently evaluated by three experts. The diagnostic performance of Diagnocat was evaluated using sensitivity, specificity, and receiver operating characteristic (ROC) curve analysis, while inter-rater agreement was assessed through Cohen’s kappa (κ). Results: Diagnocat showed high overall sensitivity (99.2%), identifying nearly all conditions marked as present by human evaluators. Specificity was low (8.7%), indicating a tendency to overdiagnose. Overall accuracy was 96%, likely influenced by the coexistence of multiple conditions. Sensitivity ranged from 77% to 96%, while specificity varied: dental restorations (66%), missing teeth (68%), periodontal bone loss (71%), and caries signs (47%). The agreement was fair for dental restorations (κ = 0.39) and missing teeth (κ = 0.37), but poor for caries signs (κ = −0.15) and periodontal bone loss (κ = −0.62). Conclusions: Diagnocat shows promise as a screening tool due to its high sensitivity, but low specificity and poor agreement for certain conditions warrant cautious interpretation alongside clinical evaluation.
- 6 September 2025
- Published by MDPI AG in Applied Sciences
- Vol. 15 (17) , 9790
Open AccessApplication of AI-Driven Software Diagnocat in Managing Diagnostic Imaging in Dentistry: A Retrospective Study
Background: This study investigates the diagnostic reliability of an artificial intelligence (AI)-based software (Diagnocat) in caries, dental restorations, missing teeth, and periodontal bone loss on panoramic radiographs (PRs), comparing its performance with evaluations from three independent dental experts serving as ground truth. Methods: A total of 104 PRs were analyzed using Diagnocat, which assigned a likelihood score (0–100%) for each condition. The same images were independently evaluated by three experts. The diagnostic performance of Diagnocat was evaluated using sensitivity, specificity, and receiver operating characteristic (ROC) curve analysis, while inter-rater agreement was assessed through Cohen’s kappa (κ). Results: Diagnocat showed high overall sensitivity (99.2%), identifying nearly all conditions marked as present by human evaluators. Specificity was low (8.7%), indicating a tendency to overdiagnose. Overall accuracy was 96%, likely influenced by the coexistence of multiple conditions. Sensitivity ranged from 77% to 96%, while specificity varied: dental restorations (66%), missing teeth (68%), periodontal bone loss (71%), and caries signs (47%). The agreement was fair for dental restorations (κ = 0.39) and missing teeth (κ = 0.37), but poor for caries signs (κ = −0.15) and periodontal bone loss (κ = −0.62). Conclusions: Diagnocat shows promise as a screening tool due to its high sensitivity, but low specificity and poor agreement for certain conditions warrant cautious interpretation alongside clinical evaluation.